Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

Seven new clinical trial grants were awarded under the Orphan Product Grants Program during the fiscal year (FY) 2024, ...

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax ...

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media reports.

The 4th Mitochondrial Dysfunction Drug Development Summit returns in 2024, to unite pharma, biotech and academia on cutting-edge research and pipeline updates expanding the therapeutic ...

The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an ...

UCB taps new UK head. Belgium-based global biopharmaceutical company UCB welcomed Nico Reynders as its new general manager ...

A functional point of contact (FPOC) is a dedicated liaison in each functional area responsible for evaluating and ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AI has the potential to transform pharmaceutical supply chains by enhancing visibility and predicting disruptions. Traditional supply chains often suffer from a lack of transparency, making it ...

UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA. The Manchester-based company said ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...